来源：生物谷 2013-08-03 18:14
2013年8月3日讯 /生物谷BIOON/ --Unicef计划旨在向全球的贫穷国家提供价格低廉的肺炎球菌疫苗以提高其卫生水平。这项计划在一开始便获得极大成功。然而目前，Unicef计划面临着需求量远大于供应量的问题。为了解决这一问题，Unicef方面与其疫苗供应商葛兰素史克和辉瑞公司进行谈判，两家公司同意未来以更加低廉的价格提供更多的疫苗。葛兰素史克和辉瑞同意在2013年到2016年额外提供5000万份疫苗供给Unicef计划。（生物谷Bioon.com）
详细英文报道：
The early success of a Unicef program to bring pneumococcal vaccines to poor countries has created a problem for the agency--demand is outstripping supply. To fix the problem, Unicef has negotiated new deals with GlaxoSmithKline ($GSK) and Pfizer ($PFE), securing more vaccines at lower costs.
Signing the new supply agreements gives Unicef access to an extra 50 million doses a year of GSK's Synflorix and Pfizer's Prevnar 13 from 2016. The 50 million doses are on top of vaccines GSK and Pfizer agreed to supply in deals they signed with Unicef in 2010 and 2011. From 2016 to 2020--when Unicef expects around 60 of its target countries to use pneumococcal vaccines--the agency will have an annual stockpile of 146 million shots. The additional shots will cost less than before, too, with Pfizer agreeing to a price of $3.30 per dose from 2014, compared to the $3.50 charged under the two previous deals.
Pfizer charges $130 a dose in the U.S., but some still feel the price Unicef pays is too high. In April, Médecins Sans Frontières (MSF) fingered pneumococcal and rotavirus vaccines as the cause of a 2,700% increase in the cost of fully vaccinating a child. The price is unlikely to fall significantly until a manufacturer from the developing world enters the market, though. Unicef does not expect this to happen before 2016, which is when Serum Institute of India hopes to introduce its 10-valent pneumococcal vaccine. As well as driving down costs, a vaccine from Serum would allow Unicef to fully bridge the gap between supply and demand. Unicef projects demand could top 160 million in 2017, which would cause a shortfall of around 15 million doses.
GSK and Pfizer could also increase their supply commitments, as they did in 2011 and again this week. The ultimate decision at Pfizer now rests with the firm's top lawyer, Amy Schulman, who was put in charge of the vaccine business this week as part of a company-wide reshuffle, Bloomberg reports. In the new structure, Pfizer's assets are divided into three units, with vaccines joining cancer drugs and consumer products under Schulman's leadership. The reorganization is widely seen as a step toward the possible breakup of Pfizer.
60年来首个疟疾根治新药！GSK单剂量他非诺喹Krintafel有效根治间日疟
APP专享
贫血新药！GSK与协和发酵麒麟达成战略合作，在日本商业化daprodustat
APP专享
儿科哮喘新药！GSK新型抗炎药Nucala治疗6-11岁嗜酸性粒细胞性哮喘在美进入正式审查
APP专享
呼吸新药！GSK单吸入器三联疗法Trelegy Ellipta获欧盟批准扩大慢阻肺适应症
APP专享
GSK等巨头联合推出有效率80%以上的长效HIV疗法
APP专享
HIV新药！GSK二合一复方单片DTG/3TC在美国进入审查，疗效媲美临床标准3药方案
APP专享
降低发病率54% GSK肺结核疫苗2b期结果积极
APP专享
GSK首个ImmTAC开始病人体内实体瘤临床I期实验
APP专享
针对儿科患者！GSK新型抗炎药Nucala治疗嗜酸性粒细胞性哮喘获欧盟CHMP支持批准
APP专享
HIV最新消息！GSK新的2药方案DTG/3TC一线治疗媲美临床标准3药方案，年底申请上市
APP专享
在线课堂 Webinar